社区

SINGAPORE — Singapore's government said Friday it will further ease Covid-related restrictions next

CureVac N.V.’s Chief Financial Officer Pierre Kemula is optimistic its COVID-19 vaccine could still be offered to certain age groups or as a booster, the Financial Timesreportedon Thursday.What Happened:Kemula told FT the German vaccine developer is still hopeful the jab could be offered to certain age groups or as a booster after data from CureVac’s late-stage trial of its international first-generation vaccine candidateshowed that it had only47% efficacy.“There is a lot of need for vaccines ou

Orphazyme shares tumbled more than 60% in pre-market trading. Orphazyme slashed its financial foreca

(Bloomberg) -- For all the talk of a commodities boom, some markets have now wiped out gains for the

NIO is #1 in China's electric SUV market for good reason.The company's success is driven by its brilliant innovations and marketing strategy.NIO is growing faster than Tesla, and yet, it is trading at a discount.NIO Inc. stands out for its strong market position- #1 market share in electric SUV in China- and innovation in the rapidly growing and highly competitive electric vehicle industry. This article will discuss why NIO is winning against some stiff competition, including against Tesla .In

Weak performance from Tesla stock has bullish analysts feeling disappointed these days. They are looking for catalysts to break shares out of their recent funk.That performance is flummoxing Tesla bulls. “Let’s begin with a healthy dose of intellectual honesty on the starting point for the stock,” writes Morgan Stanley analyst Adam Jonas in a Monday evening report. He is a Tesla bull rating shares Buy. His price target for the stock is $900 a share, almost 50% higher than recent levels. “Even bu